Molecular mechanisms of endothelial dysfunction in coronary microcirculation dysfunction.
Coronary blood flow regulation
Coronary microcirculation dysfunction
Coronary microvascular endothelial cells
Molecular mechanism
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
01
07
2023
medline:
21
8
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Coronary microvascular endothelial cells (CMECs) react to changes in coronary blood flow and myocardial metabolites and regulate coronary blood flow by balancing vasoconstrictors-such as endothelin-1-and the vessel dilators prostaglandin, nitric oxide, and endothelium-dependent hyperpolarizing factor. Coronary microvascular endothelial cell dysfunction is caused by several cardiovascular risk factors and chronic rheumatic diseases that impact CMEC blood flow regulation, resulting in coronary microcirculation dysfunction (CMD). The mechanisms of CMEC dysfunction are not fully understood. However, the following could be important mechanisms: the overexpression and activation of nicotinamide adenine dinucleotide phosphate oxidase (Nox), and mineralocorticoid receptors; the involvement of reactive oxygen species (ROS) caused by a decreased expression of sirtuins (SIRT3/SIRT1); forkhead box O3; and a decreased SK
Identifiants
pubmed: 37466848
doi: 10.1007/s11239-023-02862-2
pii: 10.1007/s11239-023-02862-2
doi:
Substances chimiques
SHC1 protein, human
0
Src Homology 2 Domain-Containing, Transforming Protein 1
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
388-397Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bradley C, Berry C (2022) Definition and epidemiology of coronary microvascular disease. J Nucl Cardiol 29(4):1763–1775. https://doi.org/10.1007/s12350-022-02974-x
doi: 10.1007/s12350-022-02974-x
pubmed: 35534718
pmcid: 9345825
Ong P et al (2018) International standardization of diagnostic criteria for microvascular angina. Int J Cardiol 250:16–20
pubmed: 29031990
doi: 10.1016/j.ijcard.2017.08.068
Taqueti VR, Di Carli MF (2018) Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol 72(21):2625–2641
pubmed: 30466521
pmcid: 6296779
doi: 10.1016/j.jacc.2018.09.042
Vancheri F et al (2020) Coronary microvascular dysfunction. J Clin Med 9(9):2880
pubmed: 32899944
pmcid: 7563453
doi: 10.3390/jcm9092880
Duncker DJ, Bache RJ, Merkus D (2012) Regulation of coronary resistance vessel tone in response to exercise. J Mol Cell Cardiol 52(4):802–813
pubmed: 22037538
doi: 10.1016/j.yjmcc.2011.10.007
Namani R et al (2020) Overview of mathematical modeling of myocardial blood flow regulation. Am J Physiol Heart Circ Physiol 318(4):H966–H975
pubmed: 32142361
pmcid: 7191499
doi: 10.1152/ajpheart.00563.2019
Karch R et al (2003) Fractal properties of perfusion heterogeneity in optimized arterial trees: a model study. J Gen Physiol 122(3):307–321
pubmed: 12913088
pmcid: 2234485
doi: 10.1085/jgp.200208747
Chen C et al (2016) Coronary microvascular dysfunction- epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy. Circ J 81(1):3–11
pubmed: 27904032
pmcid: 8607842
doi: 10.1253/circj.CJ-16-1002
Johnson NP, Gould KL, De Bruyne B (2021) Autoregulation of coronary blood supply in response to demand: JACC review topic of the week. J Am Coll Cardiol 77(18):2335–2345
pubmed: 33958131
doi: 10.1016/j.jacc.2021.03.293
Rogers PA et al (2006) H
pubmed: 16751285
doi: 10.1152/ajpheart.00172.2006
Otake A, Saitoh S, Takeishi Y (2010) Hydrogen peroxide generated from cardiac myocytes impacts metabolic dilation in coronary arterioles. Int Heart J 51(2):125–128
pubmed: 20379047
doi: 10.1536/ihj.51.125
Fukao M et al (1999) Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 274(16):10927–10935
pubmed: 10196172
doi: 10.1074/jbc.274.16.10927
Nava E, Llorens S (2019) The local regulation of vascular function: from an inside-outside to an outside-inside model. Front Physiol 10:729
pubmed: 31244683
pmcid: 6581701
doi: 10.3389/fphys.2019.00729
Arrebola-Moreno AL, Laclaustra M, Kaski JC (2012) Noninvasive assessment of endothelial function in clinical practice. Rev Esp Cardiol 65(1):80–90
pubmed: 22099430
doi: 10.1016/j.recesp.2011.09.012
Thijssen D et al (2019) Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J 40(30):2534–2547
pubmed: 31211361
doi: 10.1093/eurheartj/ehz350
Shimokawa H (2014) 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 35(45):3180–3193
pubmed: 25354517
doi: 10.1093/eurheartj/ehu427
Shimokawa H, Godo S (2020) Nitric oxide and endothelium-dependent hyperpolarization mediated by hydrogen peroxide in health and disease. Basic Clin Pharmacol Toxicol 127(2):92–101
pubmed: 31846200
doi: 10.1111/bcpt.13377
Matoba T et al (2003) Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol 23(7):1224–1230
pubmed: 12763764
doi: 10.1161/01.ATV.0000078601.79536.6C
Si H et al (2006) Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 99(5):537–544
pubmed: 16873714
doi: 10.1161/01.RES.0000238377.08219.0c
Brahler S et al (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119(17):2323–2332
pubmed: 19380617
doi: 10.1161/CIRCULATIONAHA.108.846634
Garland CJ, Dora KA (2017) EDH: endothelium-dependent hyperpolarization and microvascular signalling. Acta Physiol 219(1):152–161
doi: 10.1111/apha.12649
Freed JK, Gutterman DD (2017) Communication is key: mechanisms of intercellular signaling in vasodilation. J Cardiovasc Pharmacol 69(5):264–272
pubmed: 28482351
pmcid: 5424612
doi: 10.1097/FJC.0000000000000463
Schmidt K, de Wit C (2020) Endothelium-derived hyperpolarizing factor and myoendothelial coupling: the in vivo perspective. Front Physiol 11:602930
pubmed: 33424626
pmcid: 7786115
doi: 10.3389/fphys.2020.602930
Saxton SN et al (2019) Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue. Physiol Rev 99(4):1701–1763
pubmed: 31339053
doi: 10.1152/physrev.00034.2018
Sagris M et al (2021) Inflammation in coronary microvascular dysfunction. Int J Mol Sci 22(24):13471
pubmed: 34948272
pmcid: 8703507
doi: 10.3390/ijms222413471
Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271
pubmed: 23684677
doi: 10.1016/j.jacc.2013.02.092
Masi S et al (2021) Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. Eur Heart J 42(26):2590–2604
pubmed: 33257973
doi: 10.1093/eurheartj/ehaa857
Faccini A, Kaski JC, Camici PG (2016) Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. Eur Heart J 37(23):1799–1806
pubmed: 26912605
doi: 10.1093/eurheartj/ehw018
Del BM et al (2021) Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review. J Am Coll Cardiol 78(13):1352–1371
doi: 10.1016/j.jacc.2021.07.042
Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24(5):981–990
pubmed: 22286106
pmcid: 3454471
doi: 10.1016/j.cellsig.2012.01.008
Di Carli MF et al (2003) Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41(8):1387–1393
pubmed: 12706936
doi: 10.1016/S0735-1097(03)00166-9
Momose M et al (2002) Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 29(12):1675–1679
pubmed: 12458403
doi: 10.1007/s00259-002-0977-0
Kjaer A et al (2003) Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J Nucl Med 44(1):19–23
pubmed: 12515871
Quinones MJ et al (2004) Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140(9):700–708
pubmed: 15126253
doi: 10.7326/0003-4819-140-9-200405040-00009
Quercioli A et al (2012) Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging 5(8):805–815
pubmed: 22897994
doi: 10.1016/j.jcmg.2012.01.020
Quercioli A et al (2013) Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 34(27):2063–2073
pubmed: 23487518
doi: 10.1093/eurheartj/eht085
Schindler TH et al (2003) Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J Am Coll Cardiol 42(5):814–822
pubmed: 12957426
doi: 10.1016/S0735-1097(03)00851-9
Hamasaki S et al (2000) Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 35(6):1654–1660
pubmed: 10807473
doi: 10.1016/S0735-1097(00)00594-5
Rocha AM et al (2009) Endothelial and non-endothelial coronary blood flow reserve and left ventricular dysfunction in systemic hypertension. Clinics 64(4):327–335
pubmed: 19488591
pmcid: 2694462
doi: 10.1590/S1807-59322009000400011
Ahmad A et al (2020) Coronary microvascular endothelial dysfunction in patients with angina and nonobstructive coronary artery disease is associated with elevated serum homocysteine levels. J Am Heart Assoc 9(19):e017746
pubmed: 32993421
pmcid: 7792413
doi: 10.1161/JAHA.120.017746
Koller A et al (2018) Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism; a complex therapeutic design. Curr Pharm Des 24(25):2911–2920
pubmed: 29938610
doi: 10.2174/1381612824666180625125450
Ippolito S et al (2016) Recombinant human thyrotropin improves endothelial coronary flow reserve in thyroidectomized patients with differentiated thyroid cancer. Thyroid 26(11):1528–1534
pubmed: 27558484
doi: 10.1089/thy.2016.0082
Lavi S et al (2007) Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 115(20):2621–2627
pubmed: 17485580
doi: 10.1161/CIRCULATIONAHA.106.641654
Zhang Y et al (2020) NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol 17(3):170–194
pubmed: 31591535
doi: 10.1038/s41569-019-0260-8
Li Y, Zhu X, Liu X, Du A, Yu B (2019) miR-200a mediates protection of thymosin β-4 in cardiac microvascular endothelial cells as a novel mechanism under hypoxia-reoxygenation injury. J Cell Biochem 120(11):19098–19106. https://doi.org/10.1002/jcb.29237
doi: 10.1002/jcb.29237
pubmed: 31265170
Veitch S, Njock MS, Chandy M, Siraj MA, Chi L, Mak H et al (2022) MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol 21(1):31. https://doi.org/10.1186/s12933-022-01458-z
doi: 10.1186/s12933-022-01458-z
pubmed: 35209901
pmcid: 8876371
Lassegue B, Griendling KK (2010) NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30(4):653–661
pubmed: 19910640
doi: 10.1161/ATVBAHA.108.181610
Furuhashi M (2020) New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab 319(5):E827–E834
pubmed: 32893671
doi: 10.1152/ajpendo.00378.2020
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87(10):840–844
pubmed: 11073878
doi: 10.1161/01.RES.87.10.840
Tsai SH et al (2017) Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy. Cardiovasc Res 113(11):1329–1337
pubmed: 28575410
pmcid: 5852513
doi: 10.1093/cvr/cvx103
Forrester SJ et al (2018) Reactive oxygen species in metabolic and inflammatory signaling. Circ Res 122(6):877–902
pubmed: 29700084
pmcid: 5926825
doi: 10.1161/CIRCRESAHA.117.311401
Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313
pubmed: 17237347
doi: 10.1152/physrev.00044.2005
Feng J et al (2010) Endothelin-1-induced contractile responses of human coronary arterioles via endothelin—a receptors and PKC-alpha signaling pathways. Surgery 147(6):798–804
pubmed: 20079914
doi: 10.1016/j.surg.2009.11.016
Thengchaisri N et al (2015) Endothelin-1 impairs coronary arteriolar dilation: role of p38 kinase-mediated superoxide production from NADPH oxidase. J Mol Cell Cardiol 86:75–84
pubmed: 26211713
pmcid: 4558216
doi: 10.1016/j.yjmcc.2015.07.014
Arora S et al (2010) NAD(P)H oxidases in coronary artery disease. Adv Clin Chem 50:65–86
pubmed: 20521441
doi: 10.1016/S0065-2423(10)50004-0
Theuerle J et al (2019) Plasma endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular outcomes in humans. Int J Cardiol 291:168–172
pubmed: 30987836
doi: 10.1016/j.ijcard.2019.04.008
Lanza GA, Crea F (2010) Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 121(21):2317–2325
pubmed: 20516386
doi: 10.1161/CIRCULATIONAHA.109.900191
Ford TJ et al (2020) Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J 41(34):3239–3252
pubmed: 31972008
pmcid: 7557475
doi: 10.1093/eurheartj/ehz915
Meijles DN et al (2014) Molecular insights of p47phox phosphorylation dynamics in the regulation of NADPH oxidase activation and superoxide production. J Biol Chem 289(33):22759–22770
pubmed: 24970888
pmcid: 4132782
doi: 10.1074/jbc.M114.561159
Zhang C et al (2003) Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 92(3):322–329
pubmed: 12595345
doi: 10.1161/01.RES.0000056759.53828.2C
Huang A et al (2010) Impaired flow-induced dilation of coronary arterioles of dogs fed a low-salt diet: roles of ANG II, PKC, and NAD(P)H oxidase. Am J Physiol Heart Circ Physiol 299(5):H1476–H1483
pubmed: 20833958
pmcid: 2993196
doi: 10.1152/ajpheart.01250.2009
Paneni F et al (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34(31):2436–2443
pubmed: 23641007
pmcid: 3743069
doi: 10.1093/eurheartj/eht149
Gray SP et al (2013) NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127(18):1888–1902
pubmed: 23564668
doi: 10.1161/CIRCULATIONAHA.112.132159
Cury-Boaventura MF, Curi R (2005) Regulation of reactive oxygen species (ROS) production by C18 fatty acids in Jurkat and Raji cells. Clin Sci 108(3):245–253
doi: 10.1042/CS20040281
Ghosh A et al (2017) Role of free fatty acids in endothelial dysfunction. J Biomed Sci 24(1):50
pubmed: 28750629
pmcid: 5530532
doi: 10.1186/s12929-017-0357-5
Muris DM et al (2013) Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. Rev Endocr Metab Disord 14(1):29–38
pubmed: 23299657
doi: 10.1007/s11154-012-9231-7
Capurso C, Capurso A (2012) From excess adiposity to insulin resistance: the role of free fatty acids. Vasc Pharmacol 57(2–4):91–97
doi: 10.1016/j.vph.2012.05.003
Tona F et al (2014) Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr Metab Cardiovasc Dis 24(4):447–453
pubmed: 24548662
doi: 10.1016/j.numecd.2013.09.021
Panieri E, Santoro MM (2015) ROS signaling and redox biology in endothelial cells. Cell Mol Life Sci 72(17):3281–3303
pubmed: 25972278
doi: 10.1007/s00018-015-1928-9
Deng J (2021) Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction. Int J Cardiol Heart Vasc 34:100777
pubmed: 33912653
pmcid: 8065195
Brandes RP, Weissmann N, Schroder K (2014) Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic Biol Med 76:208–226
pubmed: 25157786
doi: 10.1016/j.freeradbiomed.2014.07.046
Nevitt C et al (2016) Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats. Am J Physiol Heart Circ Physiol 310(11):H1842–H1850
pubmed: 27199114
pmcid: 6345213
doi: 10.1152/ajpheart.00086.2016
Csanyi G et al (2012) Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 32(12):2966–2973
pubmed: 23087362
pmcid: 4394361
doi: 10.1161/ATVBAHA.112.300031
Bauer EM et al (2010) Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 88(3):471–481
pubmed: 20610415
pmcid: 2972685
doi: 10.1093/cvr/cvq218
Isenberg JS, Wink DA, Roberts DD (2006) Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 71(4):785–793
pubmed: 16820142
doi: 10.1016/j.cardiores.2006.05.024
Isenberg JS et al (2006) CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281(36):26069–26080
pubmed: 16835222
doi: 10.1074/jbc.M605040200
Meijles DN et al (2017) The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal 10(501):eaaj1784
pubmed: 29042481
pmcid: 5679204
doi: 10.1126/scisignal.aaj1784
Roberts DD, Isenberg JS (2021) CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes. Am J Physiol Cell Physiol 321(2):C201–C213
pubmed: 34106789
pmcid: 8424672
doi: 10.1152/ajpcell.00175.2021
Bitar MS (2019) Diabetes impairs angiogenesis and induces endothelial cell senescence by up-regulating thrombospondin-CD47-dependent signaling. Int J Mol Sci 20(3):673
pubmed: 30720765
pmcid: 6386981
doi: 10.3390/ijms20030673
Gutierrez LS, Gutierrez J (2021) Thrombospondin 1 in metabolic diseases. Front Endocrinol 12:638536
doi: 10.3389/fendo.2021.638536
Lin J et al (2016) Mst1 inhibits CMECs autophagy and participates in the development of diabetic coronary microvascular dysfunction. Sci Rep 6:34199
pubmed: 27680548
pmcid: 5040958
doi: 10.1038/srep34199
Su H et al (2020) Histone acetyltransferase p300 inhibitor improves coronary flow reserve in SIRT3 (Sirtuin 3) knockout mice. J Am Heart Assoc 9(18):e017176
pubmed: 32865093
pmcid: 7727016
doi: 10.1161/JAHA.120.017176
He X, Zeng H, Chen JX (2016) Ablation of SIRT3 causes coronary microvascular dysfunction and impairs cardiac recovery post myocardial ischemia. Int J Cardiol 215:349–357
pubmed: 27128560
pmcid: 4890543
doi: 10.1016/j.ijcard.2016.04.092
Zeng H, Chen JX (2019) Sirtuin 3, endothelial metabolic reprogramming, and heart failure with preserved ejection fraction. J Cardiovasc Pharmacol 74(4):315–323
pubmed: 31425381
pmcid: 6778014
doi: 10.1097/FJC.0000000000000719
Dikalova AE et al (2020) Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress. Circ Res 126(4):439–452
pubmed: 31852393
doi: 10.1161/CIRCRESAHA.119.315767
Diao Z et al (2021) SIRT3 consolidates heterochromatin and counteracts senescence. Nucleic Acids Res 49(8):4203–4219
pubmed: 33706382
pmcid: 8096253
doi: 10.1093/nar/gkab161
Cao M et al (2022) Sirtuin 3: emerging therapeutic target for cardiovascular diseases. Free Radic Biol Med 180:63–74
pubmed: 35031448
doi: 10.1016/j.freeradbiomed.2022.01.005
He X et al (2017) Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction. J Mol Cell Cardiol 112:104–113
pubmed: 28935506
pmcid: 5647246
doi: 10.1016/j.yjmcc.2017.09.007
Tao YK et al (2017) Notch3 deficiency impairs coronary microvascular maturation and reduces cardiac recovery after myocardial ischemia. Int J Cardiol 236:413–422
pubmed: 28131704
pmcid: 5639707
doi: 10.1016/j.ijcard.2017.01.096
Zhao Y, Liu YS (2021) Longevity factor FOXO3: a key regulator in aging-related vascular diseases. Front Cardiovasc Med 8:778674
pubmed: 35004893
pmcid: 8733402
doi: 10.3389/fcvm.2021.778674
Liu Y et al (2022) MicroRNA-122-5p promotes renal fibrosis and injury in spontaneously hypertensive rats by targeting FOXO3. Exp Cell Res 411(2):113017
pubmed: 34998813
doi: 10.1016/j.yexcr.2022.113017
Zurawek M et al (2018) miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract 142:146–153
pubmed: 29859273
doi: 10.1016/j.diabres.2018.05.044
Deng L et al (2015) Inhibition of FOXO1/3 promotes vascular calcification. Arterioscler Thromb Vasc Biol 35(1):175–183
pubmed: 25378413
doi: 10.1161/ATVBAHA.114.304786
Qi XF et al (2015) FoxO3a suppresses the senescence of cardiac microvascular endothelial cells by regulating the ROS-mediated cell cycle. J Mol Cell Cardiol 81:114–126
pubmed: 25655933
doi: 10.1016/j.yjmcc.2015.01.022
Tseng AH, Shieh SS, Wang DL (2013) SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med 63:222–234
pubmed: 23665396
doi: 10.1016/j.freeradbiomed.2013.05.002
Kumar S (2019) P66Shc and vascular endothelial function. Biosci Rep 39(4):BSR20182134
pubmed: 30918103
pmcid: 6488855
doi: 10.1042/BSR20182134
Magenta A et al (2014) Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. Biomed Res Int 2014:193095
pubmed: 24734227
pmcid: 3964753
doi: 10.1155/2014/193095
Boengler K et al (2019) P66shc and its role in ischemic cardiovascular diseases. Basic Res Cardiol 114(4):29
pubmed: 31165272
doi: 10.1007/s00395-019-0738-x
Cai W et al (2008) AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 294(1):C145–C152
pubmed: 18032526
doi: 10.1152/ajpcell.00350.2007
Kim YR et al (2012) Epigenetic upregulation of p66shc mediates low-density lipoprotein cholesterol-induced endothelial cell dysfunction. Am J Physiol Heart Circ Physiol 303(2):H189–H196
pubmed: 22661506
pmcid: 3404699
doi: 10.1152/ajpheart.01218.2011
Shi Y et al (2011) Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arterioscler Thromb Vasc Biol 31(9):2090–2097
pubmed: 21817106
doi: 10.1161/ATVBAHA.111.229260
Kim CS et al (2011) Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovasc Res 92(3):466–475
pubmed: 21933910
pmcid: 3211975
doi: 10.1093/cvr/cvr250
Pellegrini M, Baldari CT (2009) Apoptosis and oxidative stress-related diseases: the p66Shc connection. Curr Mol Med 9(3):392–398
pubmed: 19355920
doi: 10.2174/156652409787847254
Khanday FA et al (2006) Sos-mediated activation of rac1 by p66shc. J Cell Biol 172(6):817–822
pubmed: 16520382
pmcid: 2063726
doi: 10.1083/jcb.200506001
Acevedo A, Gonzalez-Billault C (2018) Crosstalk between Rac1-mediated actin regulation and ROS production. Free Radic Biol Med 116:101–113
pubmed: 29330095
doi: 10.1016/j.freeradbiomed.2018.01.008
Aslam M et al (2011) Intermedin induces loss of coronary microvascular endothelial barrier via derangement of actin cytoskeleton: role of RhoA and Rac1. Cardiovasc Res 92(2):276–286
pubmed: 21816966
doi: 10.1093/cvr/cvr213
Gunduz D et al (2010) Insulin stabilizes microvascular endothelial barrier function via phosphatidylinositol 3-kinase/Akt-mediated Rac1 activation. Arterioscler Thromb Vasc Biol 30(6):1237–1245
pubmed: 20339116
doi: 10.1161/ATVBAHA.110.203901
Guo J et al (2009) p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 104(5):660–669
pubmed: 19168439
pmcid: 2861587
doi: 10.1161/CIRCRESAHA.108.186288
Ohura-Kajitani S et al (2020) Marked impairment of endothelium-dependent digital vasodilatations in patients with microvascular angina: evidence for systemic small artery disease. Arterioscler Thromb Vasc Biol 40(5):1400–1412
pubmed: 32237907
doi: 10.1161/ATVBAHA.119.313704
Liu Y et al (2015) Inactivation of endothelial small/intermediate conductance of calcium-activated potassium channels contributes to coronary arteriolar dysfunction in diabetic patients. J Am Heart Assoc 4(8):e002062
pubmed: 26304940
pmcid: 4599465
doi: 10.1161/JAHA.115.002062
Liu Y et al (2018) Decreased coronary arteriolar response to KCa channel opener after cardioplegic arrest in diabetic patients. Mol Cell Biochem 445(1–2):187–194
pubmed: 29305679
pmcid: 6033646
doi: 10.1007/s11010-017-3264-x
Liu Y et al (2020) Metabolic regulation of endothelial SK channels and human coronary microvascular function. Int J Cardiol 312:1–9
pubmed: 32199682
pmcid: 7388214
doi: 10.1016/j.ijcard.2020.03.028
Nietlispach F et al (2007) Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 50(1):82–88
pubmed: 17502494
doi: 10.1161/HYPERTENSIONAHA.107.088955
Lother A, Hein L (2016) Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension 68(1):6–10
pubmed: 27217405
doi: 10.1161/HYPERTENSIONAHA.116.07418
Davel AP, Anwar IJ, Jaffe IZ (2017) The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease. Curr Opin Nephrol Hypertens 26(2):97–104
pubmed: 27930384
pmcid: 5382958
Moss ME, Carvajal B, Jaffe IZ (2019) The endothelial mineralocorticoid receptor: contributions to sex differences in cardiovascular disease. Pharmacol Ther 203:107387
pubmed: 31271793
pmcid: 6848769
doi: 10.1016/j.pharmthera.2019.06.009
Garg R et al (2015) Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 64(1):236–242
pubmed: 25125488
doi: 10.2337/db14-0670
Joffe HV et al (2007) Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 92(7):2552–2558
pubmed: 17488800
doi: 10.1210/jc.2007-0393
Haas AV et al (2019) Sex Differences in coronary microvascular function in individuals with type 2 diabetes. Diabetes 68(3):631–636
pubmed: 30409780
doi: 10.2337/db18-0650
Goodwill AG et al (2021) Mineralocorticoid receptor blockade normalizes coronary resistance in obese swine independent of functional alterations in Kv channels. Basic Res Cardiol 116(1):35
pubmed: 34018061
pmcid: 8552965
doi: 10.1007/s00395-021-00879-3
Juni RP et al (2019) Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci 4(5):575–591
pubmed: 31768475
pmcid: 6872802
doi: 10.1016/j.jacbts.2019.04.003
Yasu T et al (2018) Renin-angiotensin system inhibitors can prevent intravenous lipid infusion-induced myocardial microvascular dysfunction and leukocyte activation. Circ J 82(2):494–501
pubmed: 28954968
doi: 10.1253/circj.CJ-17-0809
Chen JW et al (2002) Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 90(9):974–982
pubmed: 12398965
doi: 10.1016/S0002-9149(02)02664-4
Pauly DF et al (2011) In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 162(4):678–684
pubmed: 21982660
pmcid: 3191889
doi: 10.1016/j.ahj.2011.07.011
Piaserico S et al (2016) Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis 251:25–30
pubmed: 27236353
doi: 10.1016/j.atherosclerosis.2016.05.036
Rolski F et al (2022) T lymphocyte-derived exosomes transport MEK1/2 and ERK1/2 and induce NOX4-dependent oxidative stress in cardiac microvascular endothelial cells. Oxid Med Cell Longev 2022:2457687
pubmed: 36211827
pmcid: 9534701
doi: 10.1155/2022/2457687
Jiang X et al (2021) Protective effect of nicorandil on cardiac microvascular injury: role of mitochondrial integrity. Oxid Med Cell Longev 2021:4665632
pubmed: 34285763
pmcid: 8275446
doi: 10.1155/2021/4665632
Setoguchi S et al (2001) Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 38(2):493–498
pubmed: 11499743
doi: 10.1016/S0735-1097(01)01382-1
Adingupu DD et al (2019) SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(-/-) mice. Cardiovasc Diabetol 18(1):16
pubmed: 30732594
pmcid: 6366096
doi: 10.1186/s12933-019-0820-6
Egashira K et al (1996) Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 94(2):130–134
pubmed: 8674170
doi: 10.1161/01.CIR.94.2.130
Denardo SJ et al (2011) Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women’s Ischemia Syndrome Evaluation (WISE) ancillary study. Clin Cardiol 34(8):483–487
pubmed: 21780138
pmcid: 3151010
doi: 10.1002/clc.20935
Togni M et al (2007) Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovasc Drugs Ther 21(2):99–108
pubmed: 17235472
doi: 10.1007/s10557-006-0494-7
Johnson NP, Gould KL (2013) Physiology of endothelin in producing myocardial perfusion heterogeneity: a mechanistic study using darusentan and positron emission tomography. J Nucl Cardiol 20(5):835–844
pubmed: 23842710
pmcid: 3779022
doi: 10.1007/s12350-013-9756-5
Reriani M et al (2010) Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122(10):958–966
pubmed: 20733096
pmcid: 2946239
doi: 10.1161/CIRCULATIONAHA.110.967406
Topcu S et al (2006) Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol 65(1):75–80
doi: 10.1111/j.1365-2265.2006.02551.x
Kayikcioglu M et al (2003) Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 24(22):1999–2005
pubmed: 14613735
doi: 10.1016/S0195-668X(03)00478-0
Pizzi C et al (2004) Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 109(1):53–58
pubmed: 14699004
doi: 10.1161/01.CIR.0000100722.34034.E4
Zhan B et al (2020) Nicorandil reversed homocysteine-induced coronary microvascular dysfunction via regulating PI3K/Akt/eNOS pathway. Biomed Pharmacother 127:110121
pubmed: 32407984
doi: 10.1016/j.biopha.2020.110121
Hou J et al (2022) Positive regulation of endothelial Tom70 by metformin as a new mechanism against cardiac microvascular injury in diabetes. Mitochondrion 65:150–160
pubmed: 35779798
doi: 10.1016/j.mito.2022.06.005
Padro T et al (2020) ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease.’ Cardiovasc Res 116(4):741–755
pubmed: 32034397
pmcid: 7825482
doi: 10.1093/cvr/cvaa003
Zeng H et al (2014) Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol 306(4):H585–H597
pubmed: 24363305
doi: 10.1152/ajpheart.00821.2013
Li F et al (2021) Qiliqiangxin alleviates Ang II-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis. Life Sci 273:119239
pubmed: 33652033
doi: 10.1016/j.lfs.2021.119239
Mohri M et al (2003) Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 41(1):15–19
pubmed: 12570938
doi: 10.1016/S0735-1097(02)02632-3
Climent B et al (2014) Upregulation of SK3 and IK1 channels contributes to the enhanced endothelial calcium signaling and the preserved coronary relaxation in obese Zucker rats. PLoS ONE 9(10):e109432
pubmed: 25302606
pmcid: 4193814
doi: 10.1371/journal.pone.0109432